Particular focuses are in molecular neuroscience and its relationship to gene activities during brain repair. My area of achievements include the first demonstration of somatic gene mutation in the brain after cerebral ischemia and I was awarded two R01 (NS034810 and NS045845) and two awards from American Heart Association. These awards lead to the development of brain probes with a potential to view gene action in live brains (R21NS057556). We have participated in at least three workshops sponsored by the NIH I have developed a novel technique for magnetic resonance imaging (MRI) of gene transcripts in living subjects. This technique permits targeting, imaging, labeling and manipulation of intracellular gene transcript in live brains. As such, it represents an area of research that is poised to become the next frontier of MRI. The hospital has filed four patent applications based on our important inventions. The invention involves making a nanoparticle of less than 30 nanometers in diameter, and is composed of short nucleic acid (siDNA or siRNA) with sequence targeting specific messenger RNA (the target) and an MR contrast agent (tracer). We have demonstrated that short DNA with proper sequence will target mRNA at low dose for non-invasive imaging using MRI; regulate protein expression at high dose for gene knockdown in the brain. We now have brain probes for angiogenesis, gliosis, and gender difference in gene activities of live brains. High resolution MR imaging of intracellular RNA for cell typing holds promises to translate molecular biology into live subjects for real time, longitudinal in vivo imaging. This design should have potential for pre-clinical and perhaps clinical applications, once it is validated for application in living brains of higher species than mice.

Addiction, Neuroscience

Prof Otto-Michael Lesch is currently president of the Austrian Society of Addiction Medicine, Head of the Addiction Medicine Research Group at the Medical University of Vienna, Department of Psychiatry and Psychotherapy. Prof Lesch has been responsible for long term studies in alcohol dependence since 1972 and has organized a large number of international clinical trials and basic research studies in alcohol and tobacco dependence. He developed clinical assessment tools to define sub-groups of addiction for better treatment approaches and the Lesch Typology, devised by Professor Lesch himself, is used to categories patients with alcohol dependence into four subgroups. Prof Lesch was the secretary of the European Society for Biomedical Research on Alcoholism (ESBRA) for 12 years.

Addiction (tobacco, alcohol, opiates and amphetamines) and there interaction with temperaments, ADHD, affective disorders and developmental disorders showing that you need this knowledge to prescribe the effective antic raving medications

Professor WK Tang was appointed to professor in the Department of Psychiatry, the Chinese University of Hong Kong in 2011. Professor Tang completed his medical training at the Chinese University of Hong Kong. He joined the Chinese University of Hong Kong as an academic staff since 1999. His main research area is Neuropsychiatry in Stroke. Professor Tang has published over 100 papers in renowned journals, and has also contributed to the peer review of 40 journals. He has secured over 20 major competitive research grants. He has served the editorial boards of five scientific journals. He was also a recipient of the Young Researcher Award in 2007, awarded by the Chinese University of Hong Kong.

His main research area is the psychiatric morbidity in stroke, namely dementia, cognitive impairment, depression, anxiety, apathy, fatigue, emotional incontinence, suicidality, insomnia, pain, and quality of life. Other research areas include psychiatric morbidity in Pneumoconiosis and Parkinson’s disease, Electroconvulsive Therapy, Schizophrenia, Psychogeriatrics and Substance Abuse

Dr. Dafny received his M.S. and Ph.D. degrees from Hadassah Medical School in Jerusalem in 1965 and 1969, respectively followed by post-docs at Caltech, UCLA, and Columbia. He is currently a professor of Neurobiology at the University of Texas Medical School at Houston.

pain mechanisms, including pain suppression and electro-acupuncture, and drug abuse mechanisms, involving morphine, cocaine, amphetamines, ritalin and ecstasy. Behavioral, neurophysiological, pharmacological, endocrinological, and immunological procedures are used, primarily with the rodent as an animal model. The electrophysiological procedures used include single cell and evoked potential recording, electroencephalography (EEG), and brain stimulation. Computerized techniques are used for monitoring animal behavior.

• Since 1991 Chair of Department and Clinic of Psychiatry at Wroclaw Medical University, and head physician in charge of the 2nd Clinical Ward at Lower Silesian Center for Mental Health (DCZP)and day-care wards and outpatient's clinic at Independent Public Clinical Hospital (SPSK). • Consultant psychiatrist and epidemiologist. • Attended research internship programs at: Psychiatric University Hospital Zurich, Switzerland (1978), University of Trieste, Italy (1993) and University of Odense, Denmark (1993) • Member of The World Mental Health Survey Initiative (WMH), Polish Psychiatric Association and Polish Old Age Psychiatry Association (PTPG), Vice-President of the European Association of Geriatric Psychiatry (EAGP)(2003-2007). • Editor in chief and publisher of Psychogeriatria Polska [Polish Old Age Psychiatry], member of editorial boards of numerous medical magazines, founder and chairman of the Foundation of Mental Health (FOZP). • Author of more than 350 articles in the field of psychopharmacology, social psychiatry, epidemiology, pharmacoeconomics and history of psychiatry, including many publications with the international scope • Investigator and coordinator in research on clinical psychopharmacology and scientific projects financed by the European Union and The State Committee for Scientific Research (KBN): Evaluation of effectiveness and costs of treatment in daycare psychiatric wards in comparison with in-patient wards in various European health care systems (EDEN - 5PRUE) ( 2001-2003 ); Adaptation of CIDI (Composite International Diagnostic Interview) questionnaire for epidemiologic research in the territory of Poland (6 PO5B 00921) (2001 - 2003); European Evaluation of Coercion in Psychiatry and Harmonization of Best Clinic Practice (EUNOMIA - 5PRUE) (2002-2005); Treatment of patients with mental disorders in the European Prison System (EUPRIS - PRUE) (2005-2006); MHEEN - Mental Health European Economics Network - Phase 2: Expansion and Further Development. (2005 - 2007); European Cooperation on Dementia (EuroCoDe) (2006-2008); Development of a European Measure of Best Practice for People with Long Term Mental Illness in Institutional Care. DEMoB.inc. (2007-2009); Epidemiology of mental disorders and access to psychiatric care facilities in Poland (EZOP - financed within the framework of the Norwegian Financial Mechanism) • Andrzej Kiejna has supervised 20 doctoral theses and 5 habilitation dissertations. Under his directorship two persons were awarded the title of professor. • Professor Kiejna is the author of the concept and organizer of the modern educational, clinical and research facilities of the Chair of Psychiatry located at Wybrzeże L. Pasteura 10. • Clinician, lecturer and scientist recognized in Poland and abroad.

Public Health Psychiatry Depression Mental Health Mood Disorders Anxiety Disorders Psychosis Schizophrenia

Ronald Bradley, DO, PhD, completed the DO-PhD Program in 1984. He received a PhD in Anatomy/Neuroscience. In 2010, he was the Director of Psychiatric Services at Millcreek Community Hospital, and Clinical Professor of Psychiatry at Lake Eric College of Osteopathic Medicine in Erie, PA. Currently, he is the Genesee County Community Mental Health Medical Director in Flint; MI. Bradley specializes in addiction psychiatry. He completed a Psychiatry Residency at the University of Michigan. During his residency, he carried out research on affective disorders and substance abuse. In 1992, he received a patent for a Test Kit for Detecting and Treating Substance Abuse, which he developed. He has published more than twenty papers on substance abuse problems and treatment.

Globular bodies: a primary cause of the opacity in senile and diabetic posterior cortical subcapsular cataracts, An immunocytochemical analysis of methionine enkephalin, substance P, and glutamic acid decarboxylase within neostriatal neurons

Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Clinical Psychiatry at Columbia University and Acting Director, Division on Substance Abuse, Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic. She is the principal investigator on several federally funded grants, a T32 NIDA funded Substance Abuse Research Fellowship, a K24 Mid Career Investigator Award and collaborates on several other grants. Her research interests include pharmacologic and psychotherapeutic treatment interventions for cocaine and marijuana abuse, and treatment approaches for substance abusers with attention-deficit hyperactivity disorder and other psychiatric illnesses. Dr. Levin has over 170 articles and book chapters and serves on several advisory panels. She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry and currently serves as the Chair of the APA council on addiction psychiatry.

Substance Abuse Disorders Psychiatric Comorbidity Adult ADHD

She worked with moderate to severe teenagers and young adults with Autism teaching them life skills and to be as independent as they are capable of being. This population of people changed my impression on how much special needs individuals are able to accomplish, given the right tools and resources. My journey as a Behavior Mentor to this wonderful group of young people inspired me to finish my Masters in Counseling to help improve those families affected by autism with the resources and assistance they require.I have spent the past year providing mental health as an Intern at The Laurel House, a Domestic Violence Agency working with women and children that have been affected by Domestic Violence. Various Mental Health issues were worked on towards a path of both healing and recovery.

Addiction And Rehabilitation

Robert "Bucky" Isaacson is the president and founder of Commodity Investment Consultants and president of Future Funding Consultants. He is a former member of the Board of Directors of National Futures Association and currently serves on the Board of Directors of the National Introducing Brokers Association.

Addiction, Psychiatry

Gregory Boothroyd, Ph.D. is an author, lecturer and professor emeritus at Western Michigan University where he served as University Ombudsman, Professor of Counseling and Director of University Substance Abuse Services. His career passion is helping people rid themselves of self-defeating behaviors and replace them with life-generating behaviors. Using Self-Defeating Behavior Theory as a treatment model, he has trained thousands of professional counselors, social workers, psychologists and medical and court personnel across the country. With warm and engaging humor, he is a frequent keynote presenter at national conventions on the inception, maintenance and elimination of self-defeating behaviors. His popular workshop has been consistently received as “enjoyable, powerful and insightful.” Along with his wife, Dr. Lori Gray Boothroyd, a psychologist and certified wellness coach in Traverse City, Michigan, he is the co-author of Going Home – A Positive Emotional Guide for Promoting Life-Generating Behaviors.

Specialty Program in Alcohol and Drug Abuse

Dr. Weiss’ career has focused on treatment and clinical research with substance-dependent patients. He has received numerous NIH grants, developing integrated group therapy, an evidence-based treatment for co-occurring bipolar and substance use disorders, and leading a multi-site treatment study of prescription opioid dependence. He has authored over 300 publications, including several books, and was vice chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders. Dr. Weiss was named a member of honor by the Spanish Society for Dual Disorders in 2011, and has received numerous other awards, including the H. David Archibald Award for Outstanding Research and/or Practice in the Addictions from The Centre for Addiction and Mental Health in Toronto (2007), the Jack H. Mendelson Research Award from McLean Hospital (2012), and the Dan Anderson Research Award from the Hazelden Foundation (2012).

Our Scientific Panel of Advisors was extremely impressed with the scientific rigor of this study, its two phase methodology, and the fact it examined extended buprenorphine maintenance," stated Dr. Audrey Klein, director of the Butler Center for Research at the Hazelden Foundation. "His current work on the use of long term buprenorphine is innovative, timely, and essential given the current epidemic of prescription opioid addiction and increase in deaths related to opioid overdose.

Travelled to Jordan, 2006 Graduated from Hawler Medical University College of Medicine 2000 Started studying at Hawler Medical University College of Medicine 1998, Started studying at Erbil 1980, Born on 18 September 1980

Psychiatry

Dr. Norman Miller is a psychiatrist in East Lansing, Michigan and is affiliated with multiple hospitals in the area, including Covenant Medical Center and DMC Detroit Receiving Hospital. He received his medical degree from Howard University College of Medicine and has been in practice for 41 years. He is one of 6 doctors at Covenant Medical Center and one of 26 at DMC Detroit Receiving Hospital who specialize in Psychiatry.

Addiction, Psychiatric, and Neurological Expertise, Expert Review, Reports, and Testimony, Independent Medical Evaluations Attorney-Medical Malpractice, Professional Discipline, Medical Care Fraud Board Certification in Psychiatry, Neurology, Addiction Psychiatry, Forensic Psychiatry Expert Evaluations and Recommendations Specific Areas of Expertise: Drug and Alcohol Addiction, Effects of Drugs and Alcohol on Brain and Behavior, Adverse Effects of Prescription Opioid/ Narcotic, Benzodiazepines, Psychotropic Medications Competence and Criminal Responsibility, Probate Contests, Disability Claims

Alcohol addiction is a very complex psychiatric disease with psychological, behavioural and somatic components. For two decades I am working on animal models of excessive alcohol drinking and alcohol addiction in order to decipher neurobiological bases of the pathology and to find new therapeutics. As addiction is considered as a pathological memory process we investigate synaptic plasticity changes and real time measurement of dopamine transmission to challenge current hypotheses of addiction. My lab has now set up an original model of binge drinking in rat using an ethanol operant self-administration procedure and the gold standard to investigate addictive behaviour. In the latter model rodents are made dependent upon alcohol and display both physical and psychological signs of dependence. In this model the vulnerability to develop the more servere phenotype of dependence is explored. We are also interested by investigating the pathophysiology of alcoholic liver disease. An important question is also the long term impact of early life ethanol exposure (in utero and adolescence) on brain functioning and vulnerability to addiction. We use both clinical and preclinical studies to answer this question. Recently we have also set up an animal model of the comorbidity schizophrenia-alcohol abuse in order to investigate the neurobiological bases of the comorbidity.

Physiologie Addictologie, Neurosciences Neuropsychopharmacologie

Associate Professor Michael McDonough has over thirty years experience as a specialist in Addiction Medicine and is currently employed as Director, Addiction Medicine & Toxicology Unit at Western Health (based at Footscray Hospital); at Western Health, he has been engaged in a variety of Drug related committees including Pharmaceutical Utilisation, Medication Safety and he is currently chairman of the ADR Committee. The Addiction Medicine & Toxicology Unit at Western Health provides treatment for inpatients and outpatients referred because of tertiary problems related to Substance Use Disorders/Addictions with significant medical co-morbidity; this service also operates TeleHeath and satellite clinics to rural Victoria. A/Prof. McDonough teaches undergraduate and postgraduate students and has a special interest in Quality Use of Medicines, particularly in relation to Addiction Medicine practise and authored papers (including in Australian Prescriber) on Opioid and Alcohol Use disorders. A/Prof. McDonough has previously served as Chief Adviser in Addiction Medicine to the Department of Health (Vic), medical advisor to the AFL, Justice Health and the Poisons Committe (Dept Health); he is a continuing member of the Australian Professional Society on Alcohol and other Drugs, the Society for the Study of Addiction (UK), American Society on Addiction Medicine, the European Society of Poisons Centres & Clinical Toxicologists, Forensic and Clinical Toxicology Association and the International Association of Forensic Toxicologists; he occasionally acts as a peer reviewer for the Medical Journal of Australia, Internal Medicine Journal, Addiction and the Drug and Alcohol Review.

Addiction Medicine & Toxicology

Medical anthropology, Biocultural Critical Medical Anthropology theory, syndemics, health disparities, drug abuse, AIDS, infectious diseases, violence, health and global warming, power and health, ethical issues in research.

Epidemology, drug abuse, AIDS, infectious diseases, violence, health and global warming

The worldwide prevalence estimates of attention deficit hyperactivity disorder (ADHD)/hyperkinetic disorder (HD) are highly heterogeneous. Presently, the reasons for this discrepancy remain poorly understood. The purpose of this study was to determine the possible causes of the varied worldwide estimates of the disorder and to compute its worldwide-pooled prevalence. Method: The authors searched MEDLINE and PsycINFO databases from January 1978 to December 2005 and reviewed textbooks and reference.

Attention deficit hyperactivity disorder hyperkinetic disorder

Dr. Haddad has been studying, smoking and tobacco control regarding Arab-American youth and young adults since 1999. Specifically, her research focuses on the predictors and barriers of tobacco smoking behavior and the development of effective interventions to increase cessation rates among Arab American and under-served populations.

Addiction, Tobacco abuse

Barry M. Lester, Ph.D. is Professor of Psychiatry & Human Behavior and Pediatrics and Director of the Brown Center for the Study of Children at Risk at the Brown Alpert Medical School and Women & Infants Hospital. The Brown Center also includes the Center for Children and Families at Women & Infants Hospital. The Centers provide research and clinical services for infants at risk and their families as well as research and clinical training. Dr. Lester's research has been federally funded throughout his career. He has been heavily involved in the NIH peer review process serving on NIH study sections, the NIH National Advisory Council on Drug Abuse, the NIH Director's Pioneer Award Program and the College of the Center for Scientific Review. He is past president of the International Association for Infant Mental Health and the author of more than 250 peer reviewed publications and 100 chapters and books.

Children at Risk,Pediatrics Psychiatry, and Human Behavior

Our group has been studying the treatment and pathophysiology of schizophrenia. Our work involves the use of various psychopharmacological probes (ketamine, delta-9-THC, iomazenil, etc) to evaluate the contributions of various neurotransmitter systems (NMDA, cannabinoid, GABA, etc) to the pathophysiology of schizophrenia; laboratory studies of comorbid substance abuse in schizophrenia, (alcohol, cannabis and nicotine) and clinical trials with novel agents for schizophrenia.

Behavior and Behavior Mechanisms; Mental Disorders; Behavioral Disciplines and Activities; Psychological Phenomena and Processes; Psychiatry and Psychology

Univ. Prof. Dr. Gabriele Fischer studied human medicine at the Medical University of Vienna. She received her doctor’s degree in 1984, when she started to specialize in the field of psychiatry and neurology. From 1986 – 1989, Gabriele Fischer did a fellowship at Washington University Medical School, St. Louis, Missouri USA. In 1994, she became the Medical Director of the Addiction Clinic, and in 2000, Professor of Psychiatry and Neurology at the Medical University of Vienna. Gabriele Fischer is involved in many epidemiological and psychopharmacological studies in the field of substance dependence; her special research focus is laid on substance dependence during pregnancy, particularly opioid dependence. Besides, Gabriele Fischer is consultant for several international and national groups, including the United Nations Office on Drug and Crime, the World Health Organisation and the European Parliament. She is member of the Scientific Board for Quality Control and Quality Management in Medicine, Member of General Medical Council, founding board member of: Women for women: health policy in focus and board member of the Quality Control Commission in Medicine in Austria.

Psychiatry and Psychotherapy

Janice M. Brown has more than 18 years of professional experience in etiology, prevention, and early intervention research on substance use and abuse issues. Her research has focused primarily on young adult populations (ages 18 to 25) and has included such issues as transitions to college life, alcohol use epidemiology, alcohol use in high-risk situations, self-regulation, and gender differences. Dr. Brown's work with young adult military populations has examined the role of stress in workplace functioning, the use of alcohol and risks associated with heavy drinking, and alcohol reduction interventions. Dr. Brown is the author of numerous articles, chapters, and technical reports on alcohol use issues. Her federally funded research has included projects offering brief motivational interventions to alcohol-abusing U.S. Air Force personnel and to freshmen college students, military epidemiological studies, and web-based intervention studies.

Psychology, Addiction

My laboratory uses chemical synthesis (organic and bio-organic) to produce known and novel compounds which are subsequently screened (in vitro) for their biological activity. Drug oral bioavailability may be influenced by low solubility, intrinsic instability, low membrane permeability, high first pass metabolism, and/or active excretion across the small intestine back into the intestinal lumen via efflux pumps. Consequently, we are interested and conduct fundamental research in drug metabolism, pharmacokinetics, and toxicity.

'Research' activities include: i) Medicinal Chemistry - rational drug design and Structure-Activity Relationship (SAR) elucidation; ii) computational chemistry; iii) developing novel technology to improve drug oral bioavailability; and iv) identifying new bio-analytical methodology.

My research focuses on the relations between neuroplasticity and neurotransmission that can be revealed by mapping radioligand binding and the neuroplastic changes of brain functions. The investigations explore the relation between energy metabolism and neurotransmission by recording the changes of energy metabolism and consciousness under pharmacological and other manipulations. I use PET to understand 1) the synthesis of radioligand and tracer molecules that match the neurotransmitter molecules and the behavior of these transmitters under different functional conditions of the brain, normal as well as pathological, and 2) the spatial and temporal relations among changes of cerebral blood flow, which is commonly used as a measure of brain work, and the cerebral oxygen consumption rate, which is the precise measure of this work. My collaborations focus on experiments with volunteer subjects and patients that explore the lesions and degeneration of brain in disorders such as epilepsy, ludomania, Parkinson's disease, stroke, depression, and somatization disorders, as well as disorders related to addiction. Experiments explore the restructuring of neuronal networks that follows when sensory activity is processed by healthy subjects or volunteers suffering from inborn or acquired lesions.

Brain Energetics. Integration of Molecular and Cellular Processs.